AMENDMENTS TO THE CLAIMS:

Claims 1-4 (Withdrawn)

Claims 5-12 (Canceled)

Claims 13-16 (Withdrawn)

Claims 17-29 (Canceled)

Claims 30-32 (Withdrawn)

Claim 33 (Canceled)

Claim 34-35 (Withdrawn)

36. (New) A transgenic mouse whose genome comprises a disruption in endogenous mouse glucocorticoid-induced receptor gene, wherein where the disruption is homozygous, the transgenic mouse lacks production of functional glucocorticoid-induced receptor and exhibits hyperactivity, reduced anxiety, decreased propensity toward behavioral despair, or decreased propensity toward depression.

37. (New) The transgenic mouse of claim 36, wherein the hyperactivity comprises an increase in total distance traveled in an open field environment, relative to a wild-type mouse.

38. (New) The transgenic mouse of claim 36, wherein the reduced anxiety comprises an increase in percent time spent in a central region of an open field environment, relative to a wild-type mouse.

39. (New) The transgenic mouse of claim 36, wherein the decreased propensity toward behavioral despair comprises a decrease in time spent immobile while tail suspended, relative to a wild-type mouse.

40. (New) The transgenic mouse of claim 36, wherein the decreased propensity toward depression comprises a decrease in time spent immobile while tail suspended, relative to a wild-type mouse.

41. A cell or tissue obtained from the transgenic mouse of claim 36.

42. A transgenic mouse comprising a heterozygous disruption in endogenous mouse glucocorticoid-induced receptor gene, wherein the disruption in a homozygous state inhibits production of functional glucocorticoid-induced receptor resulting in a transgenic mouse exhibiting hyperactivity, reduced anxiety, decreased propensity toward behavioral despair, or decreased propensity toward depression.

43. (New) The transgenic mouse of claim 42, wherein the hyperactivity comprises an increase in total distance traveled in an open field environment, relative to a wild-type mouse.

44. (New) The transgenic mouse of claim 42, wherein the reduced anxiety comprises an increase in percent time spent in a central region of an open field environment, relative to a wild-type mouse.

45. (New) The transgenic mouse of claim 42, wherein the decreased propensity toward behavioral despair comprises a decrease in time spent immobile while tail suspended, relative to a wild-type mouse.

46. (New) The transgenic mouse of claim 42, wherein the decreased propensity toward depression comprises a decrease in time spent immobile while tail suspended, relative to a wild-type mouse.

47. A method of producing a transgenic mouse comprising a disruption in endogenous mouse glucocorticoid-induced receptor gene, the method comprising:

(a) providing an murine embryonic stem cell comprising a disruption in endogenous mouse glucocorticoid-induced receptor gene; and

(b) introducing the murine stem cell into a pseudopregnant mouse, wherein the pseudopregnant mouse gives birth to a transgenic mouse;

wherein where the disruption is homozygous, the transgenic mouse lacks production of functional glucocorticoid-induced receptor and exhibits hyperactivity, reduced anxiety, decreased propensity toward behavioral despair, or decreased propensity toward depression.

48. The transgenic mouse produced by the method of claim 47.